Topic: Central Europe

Pharmaceuticals: Global Industry Almanac Datamonitor''s Pharmaceuticals: Global Industry Almanac is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles ...

Distribution on the pharmaceutical market in Central Europe 2010 Comparative analysis of Poland, Hungary, Romania, Czech Republic, Slovakia and Bulgaria Distribution in the pharmaceutical market in Central Europe 2010 provides an in-depth analysis of distribution in the pharmaceutical sector in six Central ...

Distribution on the pharmaceutical market in Poland 2010 Development forecasts for 2010-2012The aim of the report is to provide the complex analysis of the distribution on the pharmaceutical market in Poland. It focuses on the analysis of the main market segments i.e.:* ...

Nycomed agreed with Sanofi-Aventis and Zentiva to purchase 20 branded generic products in several Central and Eastern European countries. The agreement will notably strengthen Nycomed's market position in particular in the Czech Republic and Slovakia. In an asset transfer transaction, Nycomed will ...

The following statement was issued today by the Biotechnology Industry Organization (BIO) regarding a proposal to establish a pathway for regulatory approval of biosimilars reportedly under consideration in the Senate Committee on Health, Education, Labor and Pensions (HELP): "The new proposal purports ...

France's Sanofi-Aventis SA must sell off medicines in eastern Europe to win EU antitrust approval to buy a Czech generic drug maker, the European Commission said Wednesday.The French pharmaceutical company is paying euro1.8 billion ($2.3 billion) for Zentiva to broaden its drug ...

Updating with more details). PRAGUE (Thomson Financial) - Shares are expected to open lower after overnight falls in the US market and a mixed performance in Asia, with power group CEZ and drug maker Zentiva in focus after positive broker recommendations.. Today. ...